Dr. McDermott on Immunotherapy as a Standard of Care in RCC – OncLive
|
Dr. McDermott on Immunotherapy as a Standard of Care in RCC
OncLive David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses immunotherapy as a standard of care for patients with renal cell carcinoma (RCC). According to McDermott, immunotherapy will be the … |
